MedTrace Logo

Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells

NCT01919866 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-10-08

No results posted yet for this study

Summary

Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.

Conditions

Interventions

OTHER

Transplantation of CD3/CD19 depleted stem cells

Sponsors & Collaborators

  • University Children's Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Peter Lang, MD · University Children's Hospital Tuebingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01919866 on ClinicalTrials.gov